2.57
+0.04(+1.58%)
Currency In USD
| Previous Close | 2.53 |
| Open | 2.58 |
| Day High | 2.61 |
| Day Low | 2.57 |
| 52-Week High | 4.39 |
| 52-Week Low | 1.75 |
| Volume | 3,992 |
| Average Volume | 68,600 |
| Market Cap | 180.88M |
| PE | -5.71 |
| EPS | -0.45 |
| Moving Average 50 Days | 2.73 |
| Moving Average 200 Days | 2.62 |
| Change | 0.04 |
If you invested $1000 in Alpha Tau Medical Ltd. (DRTS) since IPO date, it would be worth $254.46 as of April 19, 2025 at a share price of $2.57. Whereas If you bought $1000 worth of Alpha Tau Medical Ltd. (DRTS) shares 3 years ago, it would be worth $258.81 as of April 19, 2025 at a share price of $2.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
GlobeNewswire Inc.
Apr 02, 2025 12:30 PM GMT
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has approved an Investigational Device Exemption (I
Alpha Tau to Participate in March Investor Conferences
GlobeNewswire Inc.
Feb 27, 2025 2:00 PM GMT
JERUSALEM, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
GlobeNewswire Inc.
Feb 24, 2025 1:30 PM GMT
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the achievement of Medical Device
Data not available